Comparison of Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Among Patients with Three-Vessel Coronary Artery Disease in the New-Generation Drug-Eluting Stents Era (From CREDO-Kyoto PCI/CABG Registry Cohort-3).

[1]  Sean M. O'Brien,et al.  Initial Invasive or Conservative Strategy for Stable Coronary Disease. , 2020, The New England journal of medicine.

[2]  P. Kolh,et al.  Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial , 2019, The Lancet.

[3]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[4]  H. Okayama,et al.  Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.

[5]  P. Serruys,et al.  Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  Samin K. Sharma,et al.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. , 2019, Journal of the American College of Cardiology.

[7]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[8]  S. Pocock,et al.  Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. , 2018, Journal of the American College of Cardiology.

[9]  V. Fuster,et al.  Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. , 2018, Journal of the American College of Cardiology.

[10]  V. Fuster,et al.  Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data , 2018, The Lancet.

[11]  P. Serruys,et al.  Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study , 2017, European heart journal.

[12]  P. Serruys,et al.  Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease: Patient-Level Pooled Analysis of the SYNTAX, PRECOMBAT, and BEST Trials. , 2017, JACC. Cardiovascular interventions.

[13]  Dual Antiplatelet Therapy Study Investigators.  Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. , 2017 .

[14]  Peter L Duffy,et al.  Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.

[15]  Takeshi Kimura,et al.  Meta-analysis of long-term clinical outcomes of everolimus-eluting stents. , 2015, The American journal of cardiology.

[16]  Takeshi Kimura,et al.  Comparison of Five-Year Outcome of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Triple-Vessel Coronary Artery Disease (from the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2). , 2015, The American journal of cardiology.

[17]  E. Hannan,et al.  Everolimus-eluting stents or bypass surgery for multivessel coronary disease. , 2015, The New England journal of medicine.

[18]  A. Yeung,et al.  Trial of everolimus-eluting stents or bypass surgery for coronary disease. , 2015, The New England journal of medicine.

[19]  M. Mack,et al.  Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. , 2014, European heart journal.

[20]  Takeshi Kimura,et al.  Evolution in practice patterns and long-term outcomes of coronary revascularization from bare-metal stent era to drug-eluting stent era in Japan. , 2014, The American journal of cardiology.

[21]  Akshay S. Desai,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[22]  J. Spertus,et al.  Influence of Frailty and Health Status on Outcomes in Patients With Coronary Disease Undergoing Percutaneous Revascularization , 2011, Circulation. Cardiovascular quality and outcomes.

[23]  M. Nobuyoshi,et al.  Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan , 2011, Cardiovascular intervention and therapeutics.

[24]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[25]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[26]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[27]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.

[28]  Takeshi Kimura,et al.  Long-Term Outcomes of Coronary-Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease in the Bare-Metal Stent Era , 2008, Circulation.